Corebridge Financial Inc. Reduces Stock Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Corebridge Financial Inc. trimmed its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 5.1% in the fourth quarter, Holdings Channel reports. The institutional investor owned 112,426 shares of the medical equipment provider’s stock after selling 5,983 shares during the quarter. Corebridge Financial Inc.’s holdings in Lantheus were worth $10,058,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Janus Henderson Group PLC boosted its holdings in shares of Lantheus by 7.7% in the third quarter. Janus Henderson Group PLC now owns 3,588,571 shares of the medical equipment provider’s stock worth $393,844,000 after acquiring an additional 257,022 shares during the period. Geode Capital Management LLC lifted its holdings in Lantheus by 2.0% during the 3rd quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider’s stock worth $184,798,000 after purchasing an additional 32,551 shares in the last quarter. Reinhart Partners LLC. boosted its stake in Lantheus by 9.9% in the 4th quarter. Reinhart Partners LLC. now owns 1,366,873 shares of the medical equipment provider’s stock worth $122,280,000 after purchasing an additional 123,282 shares during the period. Swedbank AB grew its holdings in Lantheus by 53.3% during the 4th quarter. Swedbank AB now owns 1,107,243 shares of the medical equipment provider’s stock valued at $99,054,000 after buying an additional 385,000 shares in the last quarter. Finally, Portolan Capital Management LLC increased its position in shares of Lantheus by 6.1% during the third quarter. Portolan Capital Management LLC now owns 670,881 shares of the medical equipment provider’s stock valued at $73,629,000 after buying an additional 38,776 shares during the period. Institutional investors own 99.06% of the company’s stock.

Lantheus Price Performance

LNTH opened at $98.43 on Thursday. The stock’s 50 day simple moving average is $93.01 and its 200 day simple moving average is $96.47. The firm has a market cap of $6.74 billion, a price-to-earnings ratio of 16.38 and a beta of 0.38. Lantheus Holdings, Inc. has a 1 year low of $58.16 and a 1 year high of $126.89.

Lantheus (NASDAQ:LNTH) last issued its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.23). The firm had revenue of $391.11 million during the quarter, compared to the consensus estimate of $376.61 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. As a group, sell-side analysts anticipate that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Insider Activity at Lantheus

In other news, CFO Robert J. Jr. Marshall sold 10,000 shares of the company’s stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $100.52, for a total value of $1,005,200.00. Following the sale, the chief financial officer now directly owns 113,860 shares of the company’s stock, valued at $11,445,207.20. This represents a 8.07 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Mary Anne Heino sold 53,107 shares of the company’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the sale, the director now owns 440,399 shares in the company, valued at approximately $41,551,645.65. This trade represents a 10.76 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 64,109 shares of company stock worth $6,110,806 over the last quarter. Corporate insiders own 1.50% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently commented on the stock. B. Riley reduced their price target on shares of Lantheus from $127.00 to $122.00 and set a “buy” rating for the company in a research report on Friday, March 21st. The Goldman Sachs Group assumed coverage on Lantheus in a research note on Wednesday, December 18th. They issued a “buy” rating and a $143.00 target price on the stock. JMP Securities reiterated a “market outperform” rating and set a $112.00 price target on shares of Lantheus in a research report on Tuesday, January 14th. Finally, Truist Financial boosted their price objective on Lantheus from $120.00 to $127.00 and gave the stock a “buy” rating in a report on Thursday, February 27th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $129.43.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.